scholarly journals Evaluation of nasal symptoms induced by platelet activating factor, after nasal challenge in both healthy and allergic rhinitis subjects pretreated with rupatadine, levocetirizine or placebo in a cross-over study design

2013 ◽  
Vol 9 (1) ◽  
pp. 43 ◽  
Author(s):  
Rosa Muñoz-Cano ◽  
Antonio Valero ◽  
Ignacio Izquierdo ◽  
Jaume Sánchez-López ◽  
Alejandro Doménech ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Study Design ◽  
Platelet Activating Factor ◽  
Nasal Challenge ◽  
Nasal Symptoms

Release of Histamine, Prostaglandins, and Leukotrienes after Antigen Challenge in Hayfever Subjects

1988 ◽  
Vol 2 (4) ◽  
pp. 183-188 ◽  
Author(s):  
Moira Chan-Yeung ◽  
Mario Kinsella ◽  
Henry Chan ◽  
Stephen Lam ◽  
Kam S. Tse ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Allergen Challenge ◽  
Antigen Challenge ◽  
Pollen Extract ◽  
Nasal Wash ◽  
Control Subjects ◽  
Nasal Challenge ◽  
Nasal Symptoms ◽  
Mixed Grass

Nasal washes before and at intervals after nasal challenge with mixed grass pollen extract were carried out in nine patients with allergic rhinitis and four control subjects. In the nasal wash, histamine was measured using the radioenzymatic method, prostaglandins (PGs) and leukotrienes (LTs) were measured by high pressure liquid chromatography. Control subjects did not react to allergen challenge. Small amounts of histamine (0.47 ± 0.23 ng/ml) and PGD2 were found in the nasal fluid before challenge with no increase in either mediator after challenge. Leukotrienes were not found before or after challenge. Subjects with allergic rhinitis developed sneezing, rhinorrhea, and stuffy nose after challenge. High levels of histamine (5.3 ± 7.0 ng/ml) and PGD2 (2.7 ± 3.2 ng/ml) were found in the first prechallenge wash even though the subjects were asymptomatic. The second prechallenge wash showed reduction of histamine (2.8 ± 5.2 ng/ml) and PGD2 (1.4 ± 1.8 ng/ml). Five to 15 minutes after antigen challenge, there was a rise in histamine and PGD2 in four of nine subjects. No LTs were detectable in the prechallenge wash. Five of nine subjects showed a rise in LTC4 and/or LTE4, immediately after challenge. Our results showed that although nasal challenge with antigen can induce the release of mediators in seven of nine subjects with allergic rhinitis, the profile of mediator release was variable, and there was no correlation between the type or amount of mediator released and the severity of the nasal symptoms. The pathogenetic role of these mediators in pollenallergic rhinitis needs further evaluation.

Platelet-activating Factor Nasal Challenge Induces Nasal Congestion and Reduces Nasal Volume in Both Healthy Volunteers and Allergic Rhinitis Patients

2013 ◽  
Vol 27 (2) ◽  
pp. e48-e52 ◽  
Author(s):  
Rosa Muñoz-Cano ◽  
Antonio Valero ◽  
Jordi Roca-Ferrer ◽  
Joan Bartra ◽  
Jaime Sanchez-Lopez ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Healthy Volunteers ◽  
Nasal Congestion ◽  
Platelet Activating Factor ◽  
Nasal Challenge

Nasal challenge shows pathogenetic relevance of specific IgE serum antibodies for nasal symptoms caused by hexahydrophthalic anhydride

1994 ◽  
Vol 24 (5) ◽  
pp. 440-449 ◽  
Author(s):  
J. NIELSEN ◽  
. WELINDER ◽  
H. OTTOSSON ◽  
I. BENSRYD ◽  
P. VENGE ◽  
...  
Keyword(s):  
Specific Ige ◽  
Serum Antibodies ◽  
Nasal Challenge ◽  
Nasal Symptoms

MP29-02 in the Treatment of Nasal Symptoms of Seasonal Allergic Rhinitis

2011 ◽  
Vol 127 (2) ◽  
pp. AB199-AB199
Author(s):  
W. Carr ◽  
S.R. Shah ◽  
W. Wheeler ◽  
H. Sacks
Keyword(s):  
Allergic Rhinitis ◽  
Seasonal Allergic Rhinitis ◽  
Nasal Symptoms

Effects of topical budesonide and levocabastine on nasal symptoms and plasma exudation responses in seasonal allergic rhinitis

Allergy ◽  
1998 ◽  
Vol 53 (4) ◽  
pp. 367-374 ◽  
Author(s):  
C. Svensson ◽  
M. Andersson ◽  
L Greiff ◽  
L-O. Blychert ◽  
C. G. A. Persson
Keyword(s):  
Allergic Rhinitis ◽  
Seasonal Allergic Rhinitis ◽  
Nasal Symptoms ◽  
Plasma Exudation

scholarly journals Evaluation of efficacy and safety of montelukast and levocetirizine FDC tablet compared to montelukast and levocetirizine tablet in patients with seasonal allergic rhinitis: a randomized, double blind, multicentre, phase III trial

2020 ◽  
Vol 7 (1) ◽  
pp. 83
Author(s):  
Sagar Panchal ◽  
Saiprasad Patil ◽  
Hanmant Barkate
Keyword(s):  
Quality Of Life ◽  
Allergic Rhinitis ◽  
Seasonal Allergic Rhinitis ◽  
Phase Iii ◽  
Fixed Dose ◽  
Controlled Study ◽  
Global Evaluation ◽  
Double Blind ◽  
Nasal Symptoms

<p class="abstract"><strong>Background:</strong> To evaluate efficacy, safety and tolerability of Montelukast 10 mg+levocetirizine 5 mg  FDC compared to either montelukast 10 mg or levocetirizine 5 mg given alone in seasonal allergic rhinitis (SAR) patients.</p><p class="abstract"><strong>Methods:</strong> Phase III, multicentre, randomized, double blind, parallel group, active controlled study was conducted in 279 SAR patients at 16 sites across India. Efficacy was assessed using daytime nasal symptoms score (Primary efficacy outcome), night-time symptoms score, daytime eye symptom score, patient's global evaluation, physician's global evaluation, rhino-conjunctivitis quality-of-life score.  </p><p class="abstract"><strong>Results:</strong> At end of treatment there was statistically significant evidence from the per protocol analysis that patients on FDC had a greater improvement in change from baseline in daytime nasal symptoms score than patients who received Montelukast (p=0.0266) or Levocetirizine (p=0.0409). These results were consistent with the Intent to treat analysis. Analysis of the secondary efficacy endpoints provided numerically greater improvement in the nighttime symptoms score, daytime eye symptoms score, and rhinoconjunctivitis quality-of-life scores in the FDC group as compared to the Montelukast group or Levocetirizine group. The FDC of Montelukast and Levocetirizine was found to be safe and generally well tolerated. The majority of adverse events were mild in severity, resolved without treatment and were unrelated to study medication.</p><p class="abstract"><strong>Conclusions:</strong> Fixed dose combination of Montelukast and Levocetirizine was safe, generally well tolerated and superior on efficacy compared to Montelukast or Levocetirizine in patients of seasonal allergic rhinitis.</p>

scholarly journals Can nasal nitric oxide be a biomarker to differentiate allergic and non-allergic rhinitis?

2021 ◽  
Vol 37 (1) ◽  
Author(s):  
A. F. Kalpaklioglu ◽  
A. Baccioglu ◽  
S. A. Yalim
Keyword(s):  
Nitric Oxide ◽  
Allergic Rhinitis ◽  
Severe Disease ◽  
Female Gender ◽  
Non Invasive ◽  
Nasal Nitric Oxide ◽  
Nasal Symptoms ◽  
Asthma Patients ◽  
Duration Of Disease ◽  
Non Allergic Rhinitis

Abstract Background Nasal nitric oxide (nNO), a noninvasive indicator for eosinophilic airway inflammation, has not been adequately studied in different types of rhinitis. The aim of this study was to compare nNO levels between allergic (AR) and non-allergic rhinitis (NAR). Patients were included based on their chronic nasal symptoms. Total nasal symptoms score (TNSS) were evaluated. nNO was measured transnasally with a flow of 5 ml/s from the nostril with an NO analyzer (NIOX MINO; Aerocrine, Sweden). Results were evaluated as parts per billion (ppb). Results Four hundred forty-three patients (277 F/166 M)—337 with AR (76%) and 106 with NAR (24%)—were assessed. Patients with AR had significantly higher TNSS, more severe disease, and longer duration of disease compared to NAR group. Allergic rhinitis had significantly higher nNO levels than NAR (370 ppb vs 290 ppb) (p = 0.001). Likewise, significant differences were observed in female gender, in patients with BMI ≥ 25 kg/m2 and those without sinusitis between the two groups. When nNO were further evaluated in comorbid asthma, patients with AR w/o asthma had the highest TNSS and had significantly higher nNO level (p < 0.001). NAR+A group, with the longest duration of rhinitis, was significantly older and had the lowest nNO level (p < 0.001). Conclusions This study showed that nNO levels were significantly higher in AR patients than NAR. Although there is no recommended standard threshold for nNO, this study confirmed the utility of nNO in differentiating AR and NAR in addition to its known fast and non-invasive advantages.

Sign in / Sign up

Export Citation Format

Share Document